These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 30953541)
1. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Moreno M; Gratacós J; Torrente-Segarra V; Sanmarti R; Morlà R; Pontes C; Llop M; Juanola X; Arthritis Res Ther; 2019 Apr; 21(1):88. PubMed ID: 30953541 [TBL] [Abstract][Full Text] [Related]
2. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401 [TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs. Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955 [TBL] [Abstract][Full Text] [Related]
5. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611 [TBL] [Abstract][Full Text] [Related]
6. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831 [TBL] [Abstract][Full Text] [Related]
7. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Shimabuco AY; Gonçalves CR; Moraes JCB; Waisberg MG; Ribeiro ACM; Sampaio-Barros PD; Goldenstein-Schainberg C; Bonfa E; Saad CGS Adv Rheumatol; 2018 Dec; 58(1):40. PubMed ID: 30657103 [TBL] [Abstract][Full Text] [Related]
9. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years. Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139 [TBL] [Abstract][Full Text] [Related]
10. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy. Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532 [TBL] [Abstract][Full Text] [Related]
11. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. Heldmann F; Baraliakos X; Kiltz U; Brandt J; van der Horst-Bruinsma IE; Landewé R; Sieper J; Burmester GR; van den Bosch F; de Vlam K; Gaston H; Gruenke M; Witt M; Appelboom T; Emery P; Dougados M; Leirisalo-Repo M; Breban M; Braun J Clin Exp Rheumatol; 2016; 34(2):184-90. PubMed ID: 27049733 [TBL] [Abstract][Full Text] [Related]
13. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. Lorenzin M; Ortolan A; Frallonardo P; Oliviero F; Punzi L; Ramonda R BMC Musculoskelet Disord; 2015 Jul; 16():166. PubMed ID: 26205000 [TBL] [Abstract][Full Text] [Related]
14. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358 [TBL] [Abstract][Full Text] [Related]
15. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis. Kim M; Won JY; Choi SY; Ju JH; Park YH Am J Ophthalmol; 2016 Oct; 170():32-40. PubMed ID: 27470062 [TBL] [Abstract][Full Text] [Related]
16. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Mezières M; Alexandre C; Dougados M Rheumatology (Oxford); 2002 Nov; 41(11):1280-5. PubMed ID: 12422001 [TBL] [Abstract][Full Text] [Related]
18. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005 [TBL] [Abstract][Full Text] [Related]
19. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965 [TBL] [Abstract][Full Text] [Related]
20. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]